Adia Med Surges Ahead of Growth Timeline With Venture Medical Partnership in $25B Wound Care Market
Rhea-AI Summary
Adia Nutrition Inc. (OTCQB: ADIA) has announced a strategic partnership between its clinical division, Adia Med, and Venture Medical to enter the $25 billion U.S. wound care market. The collaboration provides Adia Med with HCPCS billable products optimized for insurance reimbursement, targeting conditions like diabetic ulcers, venous ulcers, and pressure sores.
The partnership builds on Adia Med's existing approvals with UnitedHealthcare and Aetna, with active filings for TRICARE. Venture Medical will provide patient review and preliminary insurance verification services to streamline the reimbursement process. This expansion aligns with Adia Med's strategy to create a high-margin revenue stream while expanding access to advanced wound care solutions.
Positive
- Entry into the large $25 billion U.S. wound care market
- Established insurance partnerships with major providers UnitedHealthcare and Aetna
- Access to insurance-ready HCPCS billable products through Venture Medical
- Streamlined insurance verification and reimbursement process
Negative
- Operating in highly competitive wound care market
- Success dependent on insurance approvals and reimbursement rates
News Market Reaction – ADIA
In the Aug 26 session, ADIA gained 1.11%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - August 26, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a bold leader in regenerative medicine and personalized healthcare, today announced a thrilling partnership between its clinical division, Adia Med, and Venture Medical. This electrifying collaboration launches Adia Med into the epicenter of insurance-ready wound repair, igniting a high-margin revenue stream within the colossal
Venture Medical Logo
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/263748_venturemedicallogo_pr.jpg
Building on the momentum of its current nationwide commercial campaign for Adia Med, this strategic alliance with Venture Medical positions the company to capture a significant share of the rapidly growing wound care sector while making innovative care more accessible to patients in need. From diabetic ulcers to venous ulcers, pressure sores, and chronic skin injuries, Adia Med is equipped to address a wide range of conditions with cutting-edge solutions.
Through the partnership, Venture Medical provides Adia Med with a robust portfolio of HCPCS billable products, optimized for insurance reimbursement and tailored to individual patient conditions. Their expert support in patient review and preliminary insurance verification ensures treatments align seamlessly with payer requirements, streamlining reimbursement with precision and speed.
"This partnership is a major step forward for Adia Med," said Larry Powalisz, CEO of Adia Nutrition Inc. "Venture Medical's expertise and product supply enable us to scale rapidly into a high-demand, insurance-backed market that serves millions of Americans annually. We're not only creating a powerful new revenue stream but also delivering transformative wound care solutions to patients who need them most."
This exciting expansion strengthens Adia Med's payer integration strategy, building on existing approvals with UnitedHealthcare and Aetna, alongside active filings with TRICARE. By combining these payer relationships with Venture Medical's insurance-ready wound repair products and verification support, Adia Med is poised to gain significant ground in a large, stable, and growing market.
With this forward-thinking partnership, Adia Med is advancing its mission to drive meaningful patient impact while creating lasting, high-value opportunities for shareholders. The company is ready to make a bold mark on the future of wound care.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263748